Clinical Trials Browser

Phase 2 × Ondansetron × 1 year × Clear all

NCT07381634 2026-03-11

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

348 enrolled 15 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic